Cerluten
Brain-derived peptide bioregulator complex containing AED, KED, AEDG, and KE peptides that promote neurogenesis through histone binding, restore dendritic spine architecture under neurotoxic conditions, and enhance cognitive recovery in stroke and brain injury patients
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Typical dose
1-2 capsules (0.2 g each)
Compound profile
Scientific & efficacy data
Cognitive
Peptide profile
Limited human trials
Cerluten
1-2 capsules (0.2 g each) · Once daily
Molecular formula
C11H17N3O8 (representative primary component)
- Mol. weight
- 319.3 g/mol (representative; complex contains peptides from 200-500 Da)
- CAS number
- 75007-24-8
- PubChem
- 194641
- Developed · 1990s-2000s (based on brain peptide extract research beginning in the 1980s)
- Academic research consortium
Multiple research institutions
Amino acid sequence
Sequence not publicly available or proprietaryNeuroprotection
Clinical studies show about 2 in 3 patients improved brain function. It helps protect brain cells from damage caused by aging and injury.
Post-Stroke Recovery
One study found 18% better memory test scores and 22% more blood flow to the brain after stroke. *Based on limited human trials.
Brain Cell Renewal
Lab studies show it boosts proteins that help grow new brain cells by up to 80%. Human evidence is still limited.
Dosing
How much do I take?
1-2 capsules (0.2 g each) · 1-2 times daily with meals
1-2 capsules (0.2 g each)
1-2 times daily with meals
Covers all 2 documented dose levels · 2 administration routes · timing · dose-adjustment guidance.
Suitability
Is this right for me?
Best for cognitive recovery following stroke or traumatic brain injury & neuroprotection against age-related cognitive decline and neurodegeneration
Best for
Cognitive recovery following stroke or traumatic brain injury
Cerluten is particularly well-suited for individuals focused on cognitive recovery following stroke or traumatic brain injury. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Neuroprotection against age-related cognitive decline and neurodegeneration
Cerluten is particularly well-suited for individuals focused on neuroprotection against age-related cognitive decline and neurodegeneration. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Supporting neurogenesis and neuronal repair in aging brain tissue
Cerluten is particularly well-suited for individuals focused on supporting neurogenesis and neuronal repair in aging brain tissue. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Comprehensive bioregulatory approach to brain aging using multiple complementary peptide components
Cerluten is particularly well-suited for individuals focused on comprehensive bioregulatory approach to brain aging using multiple complementary peptide components. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider alternatives if
Do not use if
Use with caution if
Not sure?
Compare Cerluten with similar peptides to find the best fit for your goals.
Administration
How do I use it?
Oral (capsule) · Sublingual (liquid drops)
Route
Cerluten is administered Oral (capsule)—no injection required
Best sites
Covers reconstitution · step-by-step technique · storage · a sample daily schedule.
Safety
Is it safe?
4 common side effects · 2 serious
Cerluten is a peptide extract from cerebral tissue of young animals that is not FDA-approved and lacks rigorous clinical safety data.
As an undefined mixture of peptides and proteins from animal sources, quality control and batch consistency cannot be guaranteed. Potential risks include allergic reactions to animal-derived proteins, contamination with microbial pathogens or prions, and unknown long-term immunological effects.
No comprehensive safety studies have been conducted in humans, and the active pharmaceutical components have never been identified or standardized. The product exists primarily in Russian and Eastern European medical markets without Western regulatory oversight.
Evidence consists of traditional clinical use in Russian medicine spanning decades and a small number of observational studies, primarily published in non-English journals. No toxicology screening, animal safety studies by modern standards, human Phase 1 data, or randomized controlled trials exist.
Published reports are mostly descriptive case series or open-label observations without proper controls or safety monitoring parameters.
Common side effects · experienced by some users
Mild headache
Transient headache during the initial days of treatment as brain neurochemistry adjusts to enhanced neuronal gene expression and modified signaling patterns.
Management: Ensure adequate hydration. Usually self-limiting within 3-5 days. Reduce dose temporarily if persistent.
Mild drowsiness
Slight fatigue or drowsiness in the first few days, particularly with the sublingual form, as neuronal activity patterns shift.
Management: Take in the morning or early afternoon. Usually resolves within the first week of use.
Mild GI discomfort
Slight nausea or stomach discomfort with oral capsule administration, common with peptide supplements.
Management: Take capsules with a small amount of food or water. Consider the sublingual form to bypass the GI tract.
Vivid dreams
Enhanced dream vividness reflecting active neuroplasticity and neural reorganization processes stimulated by the peptide complex.
Management: Generally benign and may indicate active neurogenesis. No action typically required.
Less common
These typically resolve with continued use or dose adjustment.
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Cerluten
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Cerluten should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
With other peptides
- Safe:Pinealon (EDR peptide — targeted serotonin/pineal support that complements Cerluten's broader neuronal peptide complex approach) — May be used together under medical guidance.
- Safe:Epithalon/Epithalamin (AEDG peptide — supports melatonin synthesis and neuroendocrine function alongside Cerluten's cognitive effects) — May be used together under medical guidance.
- Safe:Cortexin (brain peptide preparation — complementary neurotrophic peptide complex with overlapping but distinct mechanisms) — May be used together under medical guidance.
With medications
- Caution:Other CNS-active peptide complexes at high doses without medical guidance — potential for overlapping epigenetic effects — Use with caution—discuss with your healthcare provider.
- Caution:Strong sedatives or CNS depressants — may produce additive sedation — Use with caution—discuss with your healthcare provider.
- Caution:Immunosuppressive medications — Cerluten's component peptides have immunomodulatory properties that may interact with immunosuppression — Use with caution—discuss with your healthcare provider.
With supplements
- Safe:Multivitamins — Generally safe to take alongside Cerluten. Space doses apart if taking oral formulations to ensure optimal absorption.
- Safe:Electrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Effectiveness
How do I know it's working?
Limited human trials · first signs days 1-10
Evidence level
Limited human trials
Regulatory status
Research compound
Onset of effects
Gradual
(3-4 weeks)
How it works
Cerluten is a natural mix of short peptides from cow brain that work like molecular switches to turn on genes for brain repair and growth.
It binds to the proteins that control your DNA, allowing new nerve cells to form and protecting against aging in brain cells. This helps improve thinking after stroke and slows age-related memory loss.
The deeper mechanism
Cerluten's peptide components modulate gene expression through epigenetic mechanisms involving direct interaction with histone proteins and DNA regulatory sequences.
The AEDG component forms specific complexes with histones H1/6 and H1/3 at defined DNA-interacting sites, increasing chromatin accessibility at promoter regions of neurogenic genes.
This increases transcription of nestin, GAP43, β-tubulin III, and doublecortin mRNA by 1.6-1.8 fold, promoting neuronal differentiation. The EDR component interacts with the DNA major groove, stabilizing dendritic spine architecture through caspase-3 inhibition.
The KED component stimulates IGF1 expression by 3.5-5.6 fold through activation of FOXO1 (longevity transcription factor) and modulation of TNKS2 (telomere maintenance) at nanomolar concentrations.
The AED component interacts with AT-rich DNA sequences in the minor groove, suppressing senescence markers (p16, p21, p53) while upregulating SIRT-6 (longevity-associated deacetylase).
All peptide components inhibit MMP-9 (tissue-degrading metalloproteinase), enhance Ki-67 and CD98hc (regeneration markers), and suppress caspase-dependent apoptosis, creating a synergistic multi-pathway approach to neuronal survival, regeneration, and anti-aging.
What to expect
Days 1-10
What you might notice
- Subtle initial changes — possibly slightly improved mental clarity or mood stability
- Mild side effects (headache, drowsiness) that resolve within the first few days
- Vivid dreams indicating early neural reorganization
- No dramatic cognitive changes expected yet — epigenetic mechanisms are building
What's normal
- Effects are subtle initially — the multi-peptide complex is working at the epigenetic level to alter gene expression through histone binding and DNA interaction
- Component peptides are beginning to upregulate neurogenic markers (nestin, GAP43) and anti-aging genes (SIRT-6, IGF1)
- Clinical studies showed EEG changes developing within the 10-20 day treatment period
What's next
- Continue the full treatment course — clinical benefits were observed at 10-20 days in studies
- Track any changes in memory, attention, or mental capacity for comparison
- The histone-peptide interactions initiated now will produce cumulative protein synthesis changes
Week 2-4
What you might notice
- Improved mental capacity and ability to focus on complex tasks
- Better memory function — both formation of new memories and recall of existing ones
- Enhanced attention span and reduced mental fatigue
- In post-stroke patients: measurable improvements in neurological function and MMSE scores
- Greater cognitive resilience under stress or demanding conditions
What's normal
- This is the therapeutic window where clinical studies demonstrated significant EEG normalization
- 64.6% of patients in the 48-patient study showed significant improvement in this timeframe
- Neurogenic markers (nestin, GAP43, doublecortin) should be upregulated, supporting new neuronal development
- Dendritic spine preservation mechanisms (EDR component) are actively protecting synaptic architecture
What's next
- Complete the full course duration (20-30 days for standard; 10-20 days for clinical protocol)
- Benefits will continue to develop after the course ends as structural neuroplastic changes mature
- Plan the next course in 3-6 months to reinforce and build upon the neurological improvements
Month 1-6 (inter-course period)
What you might notice
- Sustained cognitive improvements from persistent epigenetic changes and structural neuroplasticity
- Ongoing neuroprotective benefits from upregulated SIRT-6 and antioxidant pathways
- Neurogenesis-driven improvements may continue developing for weeks after the active course
- Benefits may gradually diminish over 3-6 months, indicating readiness for the next treatment course
What's normal
- Epigenetic modifications and structural neuronal changes persist beyond the active treatment period
- Khavinson bioregulator protocols are designed as cyclical treatments with 3-6 month intervals
- Long-term clinical follow-up (1-10 years) has shown sustained neurological benefits with repeated courses
- Each subsequent course reinforces and extends the benefits from previous treatments
What's next
Signs it's working
Treatment Response
- Improvement in the primary symptoms or condition being treated
- Positive changes in relevant lab values or clinical markers
- Consistent, stable response to Cerluten over time
- Reduction in symptom frequency or severity
General Well-being
- Improved energy levels and daily functioning
- Better quality of life related to the treated condition
- Manageable or absent side effects indicating good tolerance
- Positive feedback from healthcare provider during check-ups
Not seeing results? Common reasons
- Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- Insufficient time at target dose—most compounds need several weeks to show full benefits
- Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- Individual variation in response—genetics, metabolism, and other factors affect outcomes
- Underlying conditions or medications interfering with absorption or effectiveness
- Improper storage leading to degraded product—always verify proper storage conditions
Key research
Questions
Frequently asked
What is Cerluten and how does it differ from single-peptide bioregulators?
Cerluten is a natural peptide complex extracted from bovine cerebral cortex tissue, containing a mixture of ultrashort peptides including AED (Ala-Glu-Asp), KED (Lys-Glu-Asp), AEDG (Ala-Glu-Asp-Gly), and KE (Lys-Glu). Unlike single-peptide bioregulators such as Pinealon (one tripeptide) or Epithalon (one tetrapeptide), Cerluten provides multiple complementary peptide components that act through different but synergistic epigenetic mechanisms — histone binding, DNA major groove interaction, and DNA minor groove interaction — to produce broader neuronal effects. The composition is predominantly tripeptides (50.7%), with dipeptides (23.2%) and tetrapeptides (22.1%).
What clinical evidence supports Cerluten for brain conditions?
A clinical study at the Saint Petersburg Institute evaluated Cerluten in 48 patients with various CNS diseases including post-stroke (10 patients), craniocerebral injury (7 patients), vascular encephalopathies (5 patients), and decreased mental capacity (6 patients plus 20 with combination conditions). Treatment with 1-2 capsules 2-3 times daily for 10-20 days produced significant improvement in 64.6% and moderate improvement in 22.9% of patients, with enhanced brain bioelectric activity confirmed by EEG. A separate post-stroke study with 40 patients showed 18% improvement on MMSE cognitive scores and 22% increase in regional cerebral blood flow.
Is Cerluten safe given that it's derived from animal brain tissue?
Cerluten is manufactured through a purification process that removes all proteins above 5 kDa and eliminates foreign DNA, resulting in a mixture of only ultrashort peptides (2-5 amino acids) and free amino acids. These components are identical to peptides naturally produced in the human body. The 30+ year safety record across over 15 million patients in Russia and Eastern Europe shows no documented serious adverse effects, allergic reactions, drug dependence, or systemic toxicity. However, individuals with bovine protein allergies should exercise caution, and the theoretical concern of prion contamination — while addressed by the manufacturing purification process — should be noted.
How does the AEDG component in Cerluten promote neurogenesis?
The AEDG peptide (Ala-Glu-Asp-Gly, also known as Epithalon) promotes neurogenesis through a specific histone-binding mechanism. Molecular modeling shows it binds preferentially to histones H1/6 and H1/3 at defined DNA-interacting sites, altering chromatin accessibility. This leads to a 1.6-1.8 fold increase in mRNA expression of neurogenic differentiation markers including nestin (early neuronal marker), GAP43 (neuroplasticity protein), β-tubulin III (structural neuronal protein), and doublecortin (neuronal migration protein). These markers collectively indicate active neuronal differentiation from stem cells.
What is the recommended Cerluten cycling protocol?
The standard approach involves treatment courses of 10-30 days with intervals of 3-6 months between courses. For capsules: 1-2 capsules once daily before breakfast for 1-3 months per course. For sublingual drops: 5-6 drops 3-4 times daily for 1 month per course. Professor Khavinson recommended combining six bioregulators for 1-2 months twice yearly for comprehensive anti-aging: Endoluten (neuroendocrine), Vladonix (immune), Cerluten (brain), Sigumir (joints/bones), Svetinorm (liver), and Ventfort (blood vessels). Each subsequent course builds upon the epigenetic changes from previous treatments.
Can Cerluten help with post-stroke recovery?
Clinical evidence supports Cerluten's role in post-stroke cognitive recovery. In the 48-patient study, the 10 stroke patients showed significant improvements in mental capacity and neurological function. A separate 40-patient controlled study demonstrated 18% MMSE score improvement and 22% increased regional cerebral blood flow in the Cerluten group versus standard therapy alone. These findings suggest Cerluten can enhance standard rehabilitation when used as complementary therapy, though it should not replace established post-stroke treatment protocols.
Further reading
History & related research
History · since 2003
Restoring the Brain's Natural Language: A Russian Peptide's Journey from Laboratory to Clinical Practice
Cerluten is a synthetic brain-derived peptide bioregulator consisting of the tripeptide sequence Ala-Glu-Asp (AED). Developed by Professor Vladimir Khavinson at the St.
Read the full history of CerlutenReady for the protocol?
Every dosing tier, administration route, timing note, and dose-adjustment rule for Cerluten, on one page.